title: Hyperalphalipoproteinemia and prostaglandin I2 stability.
abstract: PGI2 is a powerful regulator of thromboresistance modulating the local platelet/vessel wall interaction. Beside the amount synthesised the availability of the biologically active compound depends on its half-life at the site of action. Plasmatic half-life of PGI2 is extremely shortened during severe infections, but also in acute myocardial infarction with extremely lowered levels of HDL-c and apoAI, the latter being described as a potential PGI2-stabilising factor. These conditions are characterised by an enhanced thrombophilic risk. This study investigated for the first time whether high levels of HDL-c (mean: 95 +/- 13 mg/dl) and apoAI (mean: 179 +/- 13 mg/dl) which have been shown epidemiologically to protect against coronary heart disease in turn might be associated with an increase in PGI2 half-life. Results were obtained from 31 healthy subjects with hyperalpha-LP as compared with 10 controls. The biological half-life of PGI2 (hyperalpha-LP: mean: 915 +/- 118 sec vs. controls: 714 +/- 70 sec; p = 0.001) was positively related to HDL-c (r = 0.8795, p < 0.001) and apoAI levels (r = 0.8025, p < 0.001). The partial correlation coefficient correcting for the association between HDL-c and apoAI levels was also significant (PGI2 to HDL-c: r = 0.6000, p < 0.001). These results suggest that the antiatherosclerotic properties of HDL might be at least partly due to an increase in PGI2 half-life.
authors.affiliation: Wilhelm Auerswald Atherosclerosis Research Group (ASF) Vienna, Austria.
authors.forename: C
authors.initials: C
authors.lastname: Pirich
authors.forename: Y
authors.initials: Y
authors.lastname: Efthimiou
authors.forename: J
authors.initials: J
authors.lastname: O'Grady
authors.forename: H
authors.initials: H
authors.lastname: Sinzinger
mesh_terms: D000293:Adolescent; D000328:Adult; D016632:Apolipoprotein A-I / Q000097:blood*; D002784:Cholesterol / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D003327:Coronary Disease / Q000453:epidemiology*; D011464:Epoprostenol / Q000493:pharmacokinetics*; D005260:Female; D006207:Half-Life; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood*; D008075:Lipoproteins, HDL / Q000097:blood*; D008297:Male; D014280:Triglycerides / Q000097:blood
chemical_list: D016632:Apolipoprotein A-I; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D008075:Lipoproteins, HDL; D014280:Triglycerides; D002784:Cholesterol; D011464:Epoprostenol